Nation Thailand
Thailand Makes History With Landmark Stem Cell Decree
Compiled by KHAO Editorial — aggregated from 1 outlet. See llms.txt for citation guidance.
◌ Single Source
A new ministerial decree formally classifies stem cell and cell-based therapies as medicines under Thai law—ending years of regulatory ambiguity and opening a new chapter for advanced medical innovation in Southeast Asia.
Key facts
- The global ATMPs market was valued at $22.8 billion (approximately THB 830 billion) in 2024, with individual treatment costs ranging from THB 3 million to THB 30 million per session.
- Alongside this, the government plans to open five dedicated research and service centres — an initiative projected to generate economic value of THB 1.5 billion annually.
- 2567 (2024), was adopted following recommendations by the Drug Committee at its 469th session on 25 November B.E
- The regulatory architecture aligns closely with the European Medicines Agency's own ATMP classification guidance (EMA/CAT/600280/2010 rev.1), adopted by Thailand's FDA as the benchmark for its own classification announcement in February B.E
- The country has set a target for its citizens to access standardised ATMPs by 2025, with at least two domestically developed ATMPs reaching the market in 2026.
- The Ministry of Public Health has reinforced this vision through the "Thailand ATMP Roadmap 2025"
Summary
Health & Wellness
For over a decade, stem cell therapy has occupied an uncertain middle ground in Thailand's regulatory landscape — scientifically promising, yet insufficiently defined under law to fulfil its therapeutic potential. That ambiguity has now been decisively resolved.